Regeneron and Tessera join forces to forge in vivo AATD gene therapy
If approved, TSRA-196 could become the first curative therapy to reach patients with AATD.
Cytiva Navigating cell therapy WP 4
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
IASO Bio gains Hong Kong approval for Fucaso application
UK-developed leukaemia cell therapy to be offered on NHS
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
USPTO grants patent to Genprex’s Reqorsa gene therapy
FDA approves Sarepta’s updated Elevidys label for DMD
FDA unveils new pathway to usher bespoke therapies to market
